IBD Treatment Market Trends

Growth Drivers

Growing Prevalence of Crohn’s Disease– As many as 780,000 people in the United States are affected by Crohn's disease, making it a widespread ailment. The disease is most prevalent in people between the ages of 15 and 35, with 25% of cases being identified by age 20. Crohn's disease is a kind of inflammatory bowel disease (IBD). Crohn’s disease causes swelling of the tissues (inflammation) in the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. This disease may lead the patients to the potentially fatal and serious complications. Hence, the increasing cases of Crohn’s disease are estimated to drive the inflammatory bowel disease treatment market growth.
Increasing Investment in Research and Development – For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD245 billion in 2020 from 2019.
Growing Spending on Rare Disease – It was observed that approximately USD 997 billion is spent on the prevention, diagnosis, treatment, and awareness of rare diseases, of which USD 449 billion goes directly toward medical expenses and around USD 437 billion accounts for indirect medical costs across the globe.
Increasing Cases of Fecal Incontinence – It was found that fecal incontinence affects between 18 to 33 patients out of every 100 hospitalized patients and 50 to 70 patients out of every 100 nursing care residents globally, respectively.

Challenges

High Treatment Cost - IBD (ulcerative colitis and Crohn's disease) treatment becomes expensive since ulcerative colitis and Crohn's disease are chronic diseases that requires treatment for a prolonged time. The treatment includes surgery, medicines, bowl rest, and others since no single treatment can cure patients with these diseases. The average cost of Crohn’s disease treatment in the first year of its diagnosis is projected to be around 25,000 U.S. dollars.
Lack of Reimbursement Facility for the Treatment of IBD
Lack of Awareness Among People Regarding Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease Treatment Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	7.6%
Base Year Market Size (2024)	USD 23.26 billion
Forecast Year Market Size (2037)	USD 60.79 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of inflammatory bowel disease treatment is evaluated at USD 24.69 billion.

The inflammatory bowel disease treatment market size was valued at USD 23.26 billion in 2024 and is likely to exceed USD 60.79 billion by the end of 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of Crohn's disease and growing spending on rare disease will boost the market growth.

North America industry is projected to account for largest revenue share by 2037, impelled by high prevalence and rising incidence of ulcerative colitis and Crohn's disease in the region.

The major players in the market include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited.

IBD Treatment Market Trends